Ballentine Partners LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ballentine Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,625 shares of the biopharmaceutical company’s stock after acquiring an additional 52 shares during the quarter. Ballentine Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $439,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 77 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $275,000. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Finally, Silvercrest Asset Management Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $1,151,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 0.3%

ALNY opened at $315.75 on Tuesday. The firm has a market capitalization of $41.17 billion, a P/E ratio of -151.08 and a beta of 0.23. The firm’s 50 day moving average is $301.17 and its 200-day moving average is $269.13. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $333.70. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm’s quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ALNY shares. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Bank of America raised their target price on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a “buy” rating in a research report on Friday. Jefferies Financial Group raised their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Finally, Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $345.70.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.